Exploring and Exploiting the Protein S100A7 as a New Target for Breast Cancer Therapy
Abstract
The following is a brief summary of the most significant achievement described herein: The conditions and mechanisms regulating S100A7 expression in breast cancer cells are not well understood. Because inflammation can regulate S100A7 in skin cells, we treated breast tumor cells with several inflammatory cytokines, including oncostatin-M (OSM), interleukin-6 (IL-6), TNF-alpha, and IL-Beta. Each of these could enhance S100A7 protein levels; however, OSM was by far the strongest inducer of S100A7 in breast cells and induced S100A7 at both the mRNA and protein levels. We noted that signaling by STAT3, PI3K and ERK1/2 were all necessary for OSM-induction of S100A7. The enhanced migratory rate bestowed by OSM stimulation was found to be dependent on S100A7. Finally, we observed that expression of S100A7 and OSM (and its receptor OSMR) were correlated in vivo, and that S100A7 may be correlated with poor patient prognosis only in the context of breast cancers that express OSMR.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2010
- Accession Number
- ADA520729
Entities
People
- Nathan West
Organizations
- BC Cancer Agency